A Food and Drug Administration advisory panel gave the go-ahead Wednesday to a new cholesterol-lowering drug from Amgen Inc. for patients with dangerously high cholesterol.
The drug, Repatha, appears to be effective at lowering cholesterol, but long-term results are still needed to evaluate its overall benefit.
An Amgen-sponsored study on the drug’s long-term results will not be complete until 2017. The FDA often follows the panel’s advice but is not required to do so. Read more at Yahoo News.
{Andy Heller-Matzav.com Newscenter}
